Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Food-effect Study of Ecopipam Pharmacokinetics
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itraconazole,Ecopipam,Rifampicin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : Itraconazole,Ecopipam,Rifampicin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for Tourette Syndrome, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2023
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Details : Ecopipam hydrochloride is a first-in-class dopamine-1 receptor antagonist which blocks the actions of the neurotransmitter dopamine at the D1 receptor. It is currently approved to treat tourette syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Ecopipam,Probe Substrate Cocktail
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Ecopipam,Probe Substrate Cocktail
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is evaluating ecopipam, an investigational first-in-class drug, to determine whether it may help improve the ability to get words out without stuttering.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2021
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Details : First adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.”
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Ecopipam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable